LoginSearch the Site |
BioRunUp Run-Up Valuation Report for MNKD Released
publication date: Oct 27, 2010
 Today we are pleased to release our detailed 9 page report on MNKD and its run-up potential. This PDF report contains detailed analysis of the following: MNKD's history Drug market Market share Financials Potential obstacles Technicals Approval values with and without the approval of BIOD's Linjeta. Approval values if MNKD receives a financial 'spotter' before the PDUFA date This detailed analysis and run-up valuation is available for BioRunUp.com subscribers. We also have detailed valuation reports for the following companies: Benefits of a BioRunUp.com membership include: - Detailed Reports on Upcoming FDA / Clinical Trades - Analyst Reports with consistently updated summaries (Sample) - Run-Up Valuation Studies (Sample) - Weekly Newsletter (Sample) - Email / SMS (Text Message) Alerts of critical news (Sample) - A New Clinical Calendar (Sample) - Screenshots of BioRunUp and mikehavRx's Trading Accounts - BioRunUp Forums - A community of informed traders - Merger with mikehavRx.com to offer combined service - A More Detailed FDA Calendar, linked to PDF reports - Historical FDA Tracker - BioRunUp Live Newsfeed - Spreadsheet download for clinical / regulatory catalyst calendar plus integrated Google Docs / Finance tracking - Mike Havrilla's portfolio and stock watch list along with Profit.ly stock trades and performance stats - Corporate Event Google Calendar tracking for bio-catalyst stocks - Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates - HavRx Healthcare Sub-Sector Indexes - Increased Organization of Tracking Upcoming Catalysts - A Unique Ratings System to Grade Catalysts - A Growing Focus on Upcoming Clinical Trial Catalysts - Direct Email Communication - Affiliate Program, earn $50 for every referral who joins |
